Maximizing the benefits of using biosimilars in Egypt

Journal of Pharmaceutical Policy and Practice

Research

Mariam Eldebeiky¹  Shaimaa Akeel¹  Mary GamaI¹  Ahmed Elagamy¹  Remonda Refaat¹  Monica Talaat²  Sohir Abdelhamid³  Amr Shafik Saad⁴  Nader Fasseeh⁵  Nagwan Abdel Rahman⁶  Akram Mahmoud⁶  Khaled Elshazly⁷  Zoltán Kaló⁸  Baher Elezbawy⁹  Kareem Ahmed El-Fass⁹  Sherif Abaza⁹  Ahmad Nader Fasseeh^1,10  Noha Hayek^1,11  Rania Ahmed Abdelaziz^1,12  Ahmed Seyam^1,12  Noura Maher Mohamed^1,12  Amal Samir Sedrak^1,13 

[1] Egyptian Authority for Unified Procurement, Medical Supply and Technology Management, Cairo, Egypt;Egyptian Drug Authority, Cairo, Egypt;Egyptian Parliament Health Sector, Cairo, Egypt;Faculty of Medicine, Ain Shams University, Cairo, Egypt;Faculty of Medicine, Alexandria University, Alexandria, Egypt;Health Insurance Organization, Cairo, Egypt;Presidential Program for Women’s Health, Cairo, Egypt;Semmelweis University, Budapest, Hungary;Syreon Research Institute, Budapest, Hungary;Syreon Middle East, Alexandria, Egypt;Syreon Middle East, Alexandria, Egypt;Faculty of Pharmacy, Alexandria University, Alexandria, Egypt;Theodor Bilharz Research Institute, Giza, Egypt;Universal Health Insurance Authority, Cairo, Egypt;Universal Health Insurance Authority, Cairo, Egypt;Faculty of Medicine, Cairo University, Cairo, Egypt;

关键词: Biosimilars;    Health policy;    Healthcare sustainability;    Patient access;    Reimbursement;   

DOI  :  10.1186/s40545-023-00581-w

 received in 2023-02-04, accepted in 2023-06-06,  发布年份 2023

来源: Springer

【 摘 要 】

BackgroundBiosimilars constitute a pathway for sustainable financing of healthcare systems in the era of expensive biologics. However, such a pathway is not free of challenges. Since the biosimilars market is expanding in Egypt, there is an urgent need for a policy framework to optimize their use and diffusion in the market. We aim to characterize a national framework based on the experiences of other countries and consultation with local experts.MethodsA narrative literature review was conducted to identify biosimilars’ policy elements worldwide. A workshop was organized with experts to discuss the narrative review findings and create consensus on recommendations.ResultsThe narrative literature review highlighted the need for biosimilar policy actions in four areas: market authorization, pricing, reimbursement, and uptake. Eighteen experts representing the Egyptian healthcare authorities attended the workshop. The most significant conclusions from the workshop included setting the price of the biosimilar at 30–40% less than its originator’s price and establishing financing protocols, in which the more expensive biologics with significant price premiums should be excluded from the formulary.ConclusionsA summarized national framework policy recommendation for biosimilars was created by local experts from the main public healthcare entities in Egypt. These recommendations coincide with the international policies adopted across different countries that aim to improve patient access while sustaining health expenditure.

【 授权许可】

CC BY   
© The Author(s) 2023